P-5091
P-5091 Basic information
- Product Name:
- P-5091
- Synonyms:
-
- 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone
- P5091, >=98%
- CS-726
- P5091; P-005091; P 005091; P 5091; P-5091
- 1-[5-(2,3-Dichloro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone
- Ethanone, 1-[5-[(2,3-dichlorophenyl)thio]-4-nitro-2-thienyl]-
- 1-[5-[(2,3-Dichlorophenyl)thio]-4-nitro-2-thienyl]-ethanone P005091
- P005091(P5091)
- CAS:
- 882257-11-6
- MF:
- C12H7Cl2NO3S2
- MW:
- 348.22
- Product Categories:
-
- Inhibitors
- Mol File:
- 882257-11-6.mol
P-5091 Chemical Properties
- Boiling point:
- 452.4±45.0 °C(Predicted)
- Density
- 1.60±0.1 g/cm3(Predicted)
- storage temp.
- 2-8°C
- solubility
- DMSO: soluble10mg/mL, clear
- form
- powder
- color
- light yellow to dark yellow
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
P-5091 Usage And Synthesis
Description
P5091 (882257-11-6) is a selective inhibitor of the ubiquitin-specific protease USP7 ( IC50=4.2 μM).1,2 Induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.1?P5091 displays antiangiogenic activity in vivo.2?Cell permeable
Uses
P005091 is a selective dual inhibitor of the cancer-related deubiquitylating proteases USP7 and USP47.
Uses
P5091 has been used:
- as a ubiquitin specific peptidase 47 (USP47) inhibitor in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to evaluate the cellular viability of MCF-10A cells
- as a USP7 inhibitor to study the regulatory role for USP7 on inflammasome activation
- as USP7 inhibitor in drug susceptibility assays to study its effect on bone marrow?resident tumor cells (BMRTCs)/ circulating tumor cells (CTCs)
Biochem/physiol Actions
P5091 plays an important role in ovarian cancer, as it can prevent the growth of cells and can promote necrosis and apoptosis.
References
1) Chauhan et al. (2012), A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance; Cancer Cell, 22 345 2) Weinstock et al. (2012), Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47; ACS Med. Chem. Lett., 3 789
P-5091Supplier
- Tel
- sales@boylechem.com
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- +86 (531) 88811783
- sales@trio-pharmatech.com (International market)
- Tel
- 0411-62910999 13889544652
- sales@meilune.com
- Tel
- 021-58950125
- info@chemexpress.com